FULC Stock Forecast: Fulcrum Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$3.69
−0.54% on the day

The 5 Wall Street analysts covering Fulcrum Therapeutics, Inc. hold a median 12-month price target of $4 — +8.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 35 of 100 as at 21 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$286.4M
Ticker Nerd rank
35/ 100
Median analyst target
$4.00
Analysts covering
5
Revenue$0.0
Operating income−$19.9M
Net income−$26.2M
Free cash flow−$16.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.1%
1M
−0.8%
YTD
−67.4%
1Y
−66.6%
From 52W high
−74.7%
From 52W low
+17.5%
$3
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Fulcrum Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
35/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
73
Volatility
56
Quality
56
Accruals
46
Revisions
41
Issuance
36
Value
24
Momentum
24

Growth (73): Sales and profits are climbing, and climbing faster than before.

Momentum (24): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

FULC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FULC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2$4$6$8$10$12$14Jan 26Apr 26Jul 26Oct 26FULCHigh $4.00Median $4.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
0
Buy
4
Hold
1
Sell
$3.00
Low
$4.00
Median
$4.00
High

The green dot is the last close — the median target sits +8.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
3 June 2026JP MorganDowngradeUnderweight—
2 June 2026HC Wainwright & Co.DowngradeNeutral$25 → $3.00
2 June 2026Leerink PartnersDowngradeMarket Perform$24 → $4.00
2 June 2026Piper SandlerDowngradeUnderweight$23 → $3.00
2 June 2026StifelDowngradeHold$25 → $3.00
2 June 2026Truist SecuritiesDowngradeHold$17 → $4.00
12 Jan 2026JP MorganInitiatesOverweight—
11 Dec 2025Truist SecuritiesMaintainsBuy—
9 Dec 2025B of A SecuritiesMaintainsUnderperform—
8 Dec 2025Cantor FitzgeraldMaintainsOverweight—
8 Dec 2025HC Wainwright & Co.MaintainsBuy—
8 Dec 2025Piper SandlerReiteratesOverweight—
8 Dec 2025RBC CapitalMaintainsSector Perform—
24 Nov 2025HC Wainwright & Co.MaintainsBuy—
24 Nov 2025Truist SecuritiesInitiatesBuy—
30 Oct 2025Piper SandlerReiteratesOverweight—
30 Oct 2025RBC CapitalMaintainsSector Perform—
20 Oct 2025HC Wainwright & Co.ReiteratesBuy—
30 July 2025RBC CapitalMaintainsSector Perform—
29 July 2025HC Wainwright & Co.UpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for FULC.

Market Radar

This page is one stock. Monday covers all of them.

FULC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

FULC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Fulcrum Therapeutics, Inc. returned −66.6% against +6.9% for the S&P 500, dividends included.

FULC vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26FULCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FULC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.9×

Cheaper than 72% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−30.5%

Higher than 28% of US stocks

Return on assets
−18.1%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Fulcrum Therapeutics, Inc. has a market value of $286.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$85.0M.

  • Diluted earnings per share, trailing twelve months: −$1.21.

  • Free cash flow in the twelve months to 30 June 2026: −$66.1M.

  • Shares outstanding: 76.3M.

  • Fulcrum Therapeutics, Inc. employs 55 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

FULC and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FULCFulcrum Therapeutics, Inc.$286.4M35
GLSIGreenwich LifeSciences, Inc.$282.6M53
BNTCBenitec Biopharma, Inc.$285.9M39
RLMDRelmada Therapeutics, Inc.$274.8M55
EVMNEvommune, Inc.$291.1M11
GALTGalectin Therapeutics, Inc.$271.3M82
NAUTNautilus Biotechnology, Inc.$269.4M70

Take a look at FULC’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Fulcrum Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about FULC

What is the FULC stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Fulcrum Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $3 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FULC stock a buy right now?

Of the 5 analysts covering Fulcrum Therapeutics, Inc., 0 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Fulcrum Therapeutics, Inc. 35 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FULC?

As at 21 Nov 2026, Fulcrum Therapeutics, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (73 of 100).

Will FULC stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +8.4% from the last close, and Ticker Nerd's factor model ranks Fulcrum Therapeutics, Inc. 35 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FULC stock forecast for 2030?

No analyst covering Fulcrum Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FULC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $4 over the next 12 months.

How has FULC stock performed over the past year?

Fulcrum Therapeutics, Inc. returned -66.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Fulcrum Therapeutics, Inc. do?

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined rare diseases. The company’s work centers on gene regulation and epigenetic control, using its discovery platform to identify drug targets that may address the root causes of disease rather than only managing symptoms.

Company

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined rare diseases. The company’s work centers on gene regulation and epigenetic control, using its discovery platform to identify drug targets that may address the root causes of disease rather than only managing symptoms. Its lead clinical program, pociredir, is designed to increase fetal hemoglobin expression and is being studied for sickle cell disease. Fulcrum Therapeutics also advances research programs in other serious hematologic and rare disorders, including beta-thalassemia and inherited aplastic anemias, while maintaining a broader focus on areas of high unmet medical need. Based in Cambridge, Massachusetts, Fulcrum Therapeutics plays a specialized role in the biotechnology market as a developer of precision medicines for challenging diseases with limited treatment options.

CEO Mr. Alexander C. Sapir · 55 employees · United States · https://www.fulcrumtx.com